Iloperidone

Indications

Iloperidone is used for: Schizophrenia

Adult Dose

Schizophrenia Day 1: 1 mg PO q12hr; increase qDay to effective dose of 6-12 mg PO q12hr Day 2: 2 mg PO q12hr, THEN increase qDay by 2 mg/day to effective dose of 6-12 mg PO q12hr; not to exceed 24 mg/day Must gradually increase dose to avoid orthostatic hypotension Hepatic impairment Mild: No dosage adjustment required Moderate: Caution advised Severe: Use not recommended

Child Dose

Safety and efficacy not established

Renal Dose

Renal impairment: Unlikely to have a significant impact since <1% of drug is excreted unchanged in urine

Administration

Contra Indications

Hypersensitivity.

Precautions

This drug is not approved for the treatment of patients with dementia-related psychosis. Prolongs QT interval; caution with other drugs/conditions that increase QTc. Not recommended in hepatic impairment. Risk of neuroleptic malignant syndrome and extrapyramidal symptoms. May cause anticholinergic side effects (eg., confusion, agitation). Blood dyscrasias (leukopenia, neutropenia, agranulocytosis) may occur. Orthostatic hypotension may occur. Lactation: not known if excreted in breast milk, do not nurse

Pregnancy-Lactation

Pregnancy Category: C Neonates exposed to antipsychotic drugs during the 3rd trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery These complications vary in severity; in some cases, symptoms have been self-limited, while in other cases neonates have required intensive care unit support and prolonged hospitalization Lactation: not known if excreted in breast milk, do not nurse

Interactions

Side Effects

Side effects of Iloperidone : >10% Dizziness (20%), Dry mouth (15%), Nausea (10%), Somnolence (10%), Tachycardia (12%) 1-10% (selected) Diarrhea, Ejaculation failure, Myalgia, Nasal congestion, Orthostatic hypotension, Palpitations, Urinary incontinence, Weight gain Frequency Not Defined (selected) Priapism

Mode of Action

May act by antagonizing a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors. Alpha blocker.